Kangstem Biotech Co., Ltd. (KOSDAQ:217730)

South Korea flag South Korea · Delayed Price · Currency is KRW
3,200.00
-30.00 (-0.93%)
At close: Apr 9, 2026
Market Cap338.59B +170.9%
Revenue (ttm)3.57B -70.6%
Net Income-10.48B
EPS-151.00
Shares Out94.05M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume628,959
Average Volume2,857,458
Open3,255.00
Previous Close3,230.00
Day's Range3,105.00 - 3,255.00
52-Week Range1,080.00 - 3,885.00
Beta0.29
RSI64.98
Earnings DateMay 11, 2026

About Kangstem Biotech

Kangstem Biotech Co., Ltd. a biopharmaceutical company, develops stem cell therapeutic products for rare and incurable diseases. The company's stem cell therapy products include Furestem-AD for treatment of subacute and chronic atopic dermatitis; Furestem-RA to treat rheumatoid arthritis; and Furestem-CD for treatment of active crohn’s disease. It also provides stem cell conditioned media, such as umbilical cord blood-derived stem cell conditioned media that includes epidermal, vascular endothelium, keratinocyte, hepatocyte, transforming, and p... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2010
Employees 97
Stock Exchange KOSDAQ
Ticker Symbol 217730
Full Company Profile

Financial Performance

In 2025, Kangstem Biotech's revenue was 3.57 billion, a decrease of -53.88% compared to the previous year's 7.75 billion. Losses were -10.48 billion, 36.7% more than in 2024.

Financial Statements